menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Higher plasma EPA level associated with reduced HF risk

heartfailure.onlinejacc.org
Literature - Block RC, Liu L, Herrington DM et al. - J Am Coll Cardiol HF 2019;7:651-661, doi.org/10.1016/j.jchf.2019.03.008

Introduction and methods

The omega-3 polyunsaturated fatty acids (ω3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are important factors of CV health [1-3], but data on CV benefit in coronary heart disease (CHD) and HF with use of supplements are contradictory. In patients with CHD, survival benefit was observed with ω3 PUFAs by prevention of sudden death [4-8] and some studies suggest that ω3 PUFAs might improve outcomes in HF patients [9-13]. In contrast, a meta-analysis comprising data of >77000 participants showed no benefit of supplemental ω3 PUFAs in patients with CHD [14]. Of note, in the meta-analysis, HF was not evaluated as an endpoint and studies using sufficient doses to achieve meaningful concentrations are lacking. Studies in a mouse model of HF have demonstrated that left ventricular function was preserved and interstitial fibrosis was prevented with dietary ω3 PUFAs at supraphysiological levels [15].

The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal cohort study including African American, Hispanic, Asian, and white adults in the US [16,17]. In this analysis of the MESA cohort, 6562 participants were included between July 2000 and July 2002. It was examined whether EPA abundance (% EPA) is associated with risk for HF. Also, the association of EPA levels with incidence of HFrEF and HFpEF was studied and whether the association between EPA and HF incidence was unique among ω3 PUFAs.

Baseline levels of 25 fatty acids (FA) were measured and 8 clusters were identified. EPA status was defined as insufficient (<1.0%), marginal (≥1.0% and ≤2.5%), or sufficient (>2.5%) to prevent HF on the basis of a prior definition of EPA levels that prevent HF in animal models [3]. Outcome was HF events, adjudicated by physicians based on medical records. For adjustments, the FA with the largest within-cluster correlation was identified as the lead FA and used as adjuster. Median follow-up was 13.0 years.

Main results

  • 73.1% of participants had insufficient plasma EPA, 2.4% had marginal levels, and 4.5% had sufficient levels. Hispanic participants had the lowest %EPA levels, with 1.4% having sufficient EPA, followed by black (4.4%), white (4.9%), and Chinese (9.8%) participants.
  • % EPA was 0.76 (0.75-0.77) in those without HF (n=6270) and 0.69 (0.64-0.74) in those with an HF event (n=292), which was significantly different (P<0.05).
  • Log %EPA was associated with reduced HF risk, regardless of HF type. After adjustment for age, sex, race and study center, the association remained significant. Adjusting for FA cluster leads, did not result in changes in the association of %EPA with HF risk. After adjustment for additional risk factor, HR was 0.73 (95%CI: 0.60-0.91, P=0.004) per unit increase in log %EPA.
  • The final adjusted HR for %DHA was 0.51 (95% CI: 0.38-0.70; P<0.0001); for proportion ω3 docosapentaenoic acid (DPA) HR was 0.59 (95% CI:0.37-0.95; P=0.03); and for %EPA plus %DHA, HR was 0.54 (95% CI: 0.39-0.73). No substantial differences were observed when only participants with HFrEF or HFpEF were included.
Higher plasma EPA level associated with reduced HF risk

Conclusion

In the MESA cohort of participants of multiple ethnicities, higher %EPA was associated with reduced HF risk, both for HFrEF and HFpEF. This inverse association was also observed for the ω3 PUFAs DPA and DHA and was strongest for EPA plus DHA. Interventions that could result in EPA levels >4.0% may reduce the incidence of HF in the general population.

Editorial comment

After a brief summary, Maggioni [18] discussed the limitations of this study. There is a low number of HFpEF cases and more importantly, there is a small number of participants with sufficiently high levels of ω3 PUFAs to be protective. Most intervention studies have used a dose of 1 gram/day, but it is questionable whether this gives CV beneficial effects. More recently, the OMEGA-REMODEL and REDUCE-IT trials have demonstrated benefit with higher doses of ω3 PUFAs. Maggioni therefore asked what the role of ω3 PUFAs in CV medicine in 2019 should be. No benefit has been observed for low dose of 1 gram/day in primary prevention, but a higher dose of 4 gram/day EPA has been demonstrated to reduce major atherothrombotic events, including CV death, in those with a history of CVD. In response to the question whether we need to go to the fish market or to the pharmacy to elevate ω3 PUFAs levels, he answered that high levels may be achieved by use of pharmacological preparations. He concluded: ‘if we want to move from hypotheses to more reliable evidence, it is probably the time to redesign adequately sized randomized clinical trials testing high dosages of omega-3 fatty acids on top of current optimized pharmacological and nonpharmacological therapies’.

References

1. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011;364:2439–50.

2. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047–67.

3. O’Connell TD, Block RC, Huang SP, Shearer GC. ω3-Polyunsaturated fatty acids for heart failure: effects of dose on efficacy and novel signaling through free fatty acid receptor 4. J Mol Cell Cardiol 2017;103:74–92.

4. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447–55.

5. Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005;7:904–9.

6. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897–903.

7. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757–61.

8. Mozaffarian D, Lemaitre RN, King IB, et al. Circulating long-chain omega-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med 2011;155:160–70.

9. Tavazzi L, Maggioni AP, Marchioli R, et al., for the GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised,

double-blind, placebo-controlled trial. Lancet 2008;372:1223–30.

10. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011;57:870–9.

11. Chrysohoou C, Metallinos G, Georgiopoulos G, et al. Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; a randomized clinical trial. Vasc Pharmacol 2016;79: 43–50.

12. Kohashi K, Nakagomi A, Saiki Y, et al. Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atherscler Thromb 2014;21:712–29.

13. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011;161:915. e1–9.

14. Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 2018;3:225–34.

15.Chen J, Shearer GC, Chen Q, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011;123:584–93.

16. Bild DE, Bluemke DA, Burke GL, et al. Multiethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871–81.

17. Block R, Kakinami L, Liebman S, Shearer GC, Kramer H, Tsai M. Cis-vaccenic acid and the Framingham risk score predict chronic kidney disease: the multi-ethnic study of atherosclerosis (MESA). Prostaglandins Leukot Essent Fatty Acids 2012; 86:175–82.

18. Maggioni AP. Omega-3 Fatty Acids and Heart Failure: Evidence and Still Open Questions. JACC Heart Fail. 2019;7:662-663

Download the slideFind this article online at JACC HF

Facebook Comments

Schedule17 May 2024